0 139

Cited 16 times in

Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay

Authors
 Hye-young Wang  ;  Sungwoo Ahn  ;  Sunghyun Kim  ;  Sunyoung Park  ;  Dongju Jung  ;  Sangjung Park  ;  Hyunju Han  ;  JooHyuk Sohn  ;  SeungIl Kim  ;  Hyeyoung Lee 
Citation
 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, Vol.20(5) : 878-890, 2015 
Journal Title
 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 
ISSN
 1341-9625 
Issue Date
2015
MeSH
Adult ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism* ; Breast Neoplasms/blood ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism* ; Female ; Humans ; Middle Aged ; Neoplastic Cells, Circulating/metabolism* ; Reverse Transcriptase Polymerase Chain Reaction* ; Young Adult
Keywords
Anti-tumor treatment ; Breast cancer ; Circulating tumor cells (CTCs) ; Molecular diagnosis ; RT-qPCR
Abstract
BACKGROUND: Breast cancer is a highly prevalent disease among women worldwide. While the expression of certain proteins within breast cancer tumors is used to determine the prognosis and select therapies, additional markers need to be identified. Circulating tumor cells (CTCs) are constituent cells that have detached from a primary tumor to circulate in the bloodstream. CTCs are considered the main source of breast cancer metastases; therefore, detection of CTCs could be a promising diagnostic method for metastatic breast cancer. METHODS: In this study, the CircleGen CTC RT-qDx assay was used to analyze the mRNA expression levels of six CTC-specific markers including EpCAM, CK19, HER2, Ki67, hTERT, and vimentin with a total of 692 peripheral whole blood samples from 221 breast cancer patients and 376 healthy individuals. RESULTS: This assay showed high specificity with multiple markers; none of the healthy controls were detected positive, whereas 21.7 and 14 % of breast cancer patients were positive for EpCAM and CK19, respectively. Of the 221 breast cancer patients, 84 (38 %), 46 (20.8 %), 83 (37.6 %), and 39 (17.6 %) were positively for HER2, Ki67, hTERT, and vimentin mRNA, respectively. Of the 84 patients who were HER2 positive, nine (4 %) were also positive for EpCAM, CK19, Ki67, hTERT, and vimentin. Of the 139 breast cancer patients who were HER2 negative, 65 (29.1 %) were negative for EpCAM, CK19, Ki67, hTERT, and vimentin. Furthermore, the EpCAM-positive population decreased from 21.5 to 8.3 % after completion of anti-tumor treatment (TP4). Similarly, the CK19, HER2, hTERT, and vimentin positives also decreased from 13.9 to 9.5 %, from 37.7 to 21.4 %, from 37.2 to 33.3 %, and from 17.5 to 14.3 %, respectively, after completion of anti-tumor treatment. In contrast, the Ki67 positives increased from 20.6 to 41.7 % after completion of anti-tumor treatment. CONCLUSIONS: mRNA overexpression of six CTC-specific markers was detected by the CircleGen CTC RT-qDx assay with high specificity, and the obtained mRNA expression levels of CTC-specific markers might provide useful criteria to select appropriate anti-tumor treatment for breast cancer patients.
Full Text
http://link.springer.com/article/10.1007%2Fs10147-015-0798-3
DOI
10.1007/s10147-015-0798-3
Appears in Collections:
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Seung Il(김승일)
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Han, Hyun Ju(한현주)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/155660
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse